The CVP – CFO of Edwards Lifesciences (EW), Scott Ullem Unloaded 25,000 Shares; Astronics (ATRO)’s Sentiment Is 0.81

Astronics Corporation (NASDAQ:ATRO) Logo

Sentiment for Astronics Corp (ATRO)

Astronics Corp (ATRO) investors sentiment decreased to 0.81 in 2018 Q1. It’s down -0.29, from 1.1 in 2017Q4. The ratio fall, as 44 investment managers increased and started new positions, while 54 decreased and sold their holdings in Astronics Corp. The investment managers in our database now have: 19.09 million shares, down from 19.21 million shares in 2017Q4. Also, the number of investment managers holding Astronics Corp in top ten positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 42 Increased: 33 New Position: 11.

Among 29 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 6 Hold. Therefore 76% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $135.79’s average target is -4.35% below currents $141.97 stock price. Edwards Lifesciences Corp had 113 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Guggenheim on Friday, February 2 with “Buy”. The rating was reinitiated by William Blair on Monday, August 28 with “Outperform”. On Friday, October 9 the stock rating was initiated by Cowen & Co with “Outperform”. Citigroup maintained the shares of EW in report on Wednesday, July 27 with “Sell” rating. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, October 25 report. BMO Capital Markets maintained it with “Outperform” rating and $114 target in Monday, April 4 report. The rating was maintained by Canaccord Genuity on Wednesday, April 25 with “Buy”. The firm has “Outperform” rating by Credit Suisse given on Monday, August 10. The firm has “Outperform” rating given on Wednesday, October 26 by RBC Capital Markets. The firm earned “Equal-Weight” rating on Thursday, July 27 by Barclays Capital.

The stock increased 0.08% or $0.11 during the last trading session, reaching $141.97. About 1.31M shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 19.08% since June 7, 2017 and is uptrending. It has outperformed by 6.51% the S&P500. Some Historical EW News: ; 22/05/2018 – EDWARDS LIFESCIENCES – EDWARDS SAPIEN 3 VALVE DATA DEMONSTRATED CONSISTENCY WITH THOSE RESULTS ACHIEVED IN EARLIER CONTROLLED CLINICAL TRIALS; 14/05/2018 – Edwards Lifesciences To Webcast Annual Meeting Of Stockholders; 24/04/2018 – Edwards Lifesciences 1Q EPS 96c; 20/04/2018 – Cramer’s lightning round: Edwards Lifesciences is simplifying heart surgery, and it’s a buy; 24/04/2018 – EDWARDS LIFESCIENCES – CONTINUES TO EXPECT THVT FY UNDERLYING SALES GROWTH RATE TO BE AT HIGHER END OF 11 PCT TO 15 PCT; 28/03/2018 – BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGAT; 22/05/2018 – Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve; 09/03/2018 MOODY’S: OUTLOOK FOR US MEDICAL PRODUCTS AND DEVICES INDUSTRY CHANGED TO POSITIVE; 24/04/2018 – Edwards Lifesciences Raises 2018 View To Adj EPS $4.50-Adj EPS $4.70; 20/04/2018 – DJ Edwards Lifesciences Corporation, Inst Holders, 1Q 2018 (EW)

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $29.92 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 54.65 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on July, 25. They expect $1.12 EPS, up 3.70% or $0.04 from last year’s $1.08 per share. EW’s profit will be $236.07 million for 31.69 P/E if the $1.12 EPS becomes a reality. After $1.22 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts -8.20% negative EPS growth.

More news for Edwards Lifesciences Corporation (NYSE:EW) were recently published by: Seekingalpha.com, which released: “Don’t Let Go Of Hasbro – Cramer’s Lightning Round (6/5/18)” on June 06, 2018. Seekingalpha.com‘s article titled: “Edwards Lifesciences: Treating The #1 Killer In America” and published on May 12, 2018 is yet another important article.

Scott Ullem is the CVP – CFO of Edwards Lifesciences Corp. He in the last few days sold 25,000 shares in the public company with the deal value amounting to precisely $3,526,761 US Dollars. The stated number is based on the reported price of $141.1 per every share. He also unloaded 25,000 shares with a total value $3,368,243 USD in the last month. Obviously, the transaction created confusion, as Mr. Scott at the moment owns 79,045 shares, accounting for 0.04% of the Company’s total market capitalization.

Since January 1, 0001, it had 0 insider purchases, and 18 insider sales for $1.49 million activity.

Analysts await Astronics Corporation (NASDAQ:ATRO) to report earnings on August, 1. They expect $0.34 EPS, up 30.77% or $0.08 from last year’s $0.26 per share. ATRO’s profit will be $9.62 million for 26.02 P/E if the $0.34 EPS becomes a reality. After $0.11 actual EPS reported by Astronics Corporation for the previous quarter, Wall Street now forecasts 209.09% EPS growth.

The stock decreased 1.06% or $0.38 during the last trading session, reaching $35.39. About 75,114 shares traded. Astronics Corporation (ATRO) has risen 13.90% since June 7, 2017 and is uptrending. It has outperformed by 1.33% the S&P500. Some Historical ATRO News: ; 10/04/2018 – Astronics AeroSat Certifies FliteStream® SATCOM Connectivity and AeroShield™ Radome Systems; 09/05/2018 – ASTRONICS CORP – QTRLY BOOKINGS WERE STRONG AT $196.2 MILLION; 09/05/2018 – ASTRONICS CORP – 89 PCT OF BACKLOG AT QTR-END IS EXPECTED TO SHIP IN 2018; 22/04/2018 – DJ Astronics Corporation Class B, Inst Holders, 1Q 2018 (ATROB); 02/04/2018 – ASTRONICS CORP – UNIT SELECTED BY MULTIPLE ASIA-PACIFIC AIRLINES TO INSTALL EMPOWER IN-SEAT POWER AND FLIGHT DECK POWER SYSTEMS; 09/05/2018 – ASTRONICS CORP – SEES 2018 CONSOLIDATED SALES IN THE RANGE OF $765 MILLION TO $815 MILLION; 15/05/2018 – Astronics Ballard Technology’s webFB® Selected by Norwegian Air Shuttle ASA for Fleet Data Acquisition; 16/05/2018 – Astronics May Face Pressure, Industry Posts 35th Straight Drop; 15/05/2018 – Astronics Connectivity Systems and Certification Receives STCs for EmPower® Installed in the Flight Deck; 08/03/2018 Astronics at Management Roadshow Hosted By CL King Today

More news for Astronics Corporation (NASDAQ:ATRO) were recently published by: Seekingalpha.com, which released: “Astronics down 4% post Q1 results” on May 09, 2018. Seekingalpha.com‘s article titled: “Astronics’ (ATRO) CEO Peter Gundermann on Q1 2018 Results – Earnings Call Transcript” and published on May 09, 2018 is yet another important article.

Astronics Corporation (NASDAQ:ATRO) Institutional Positions Chart